Mosunetuzumab
id:
mosunetuzumab-274-965275
title:
Mosunetuzumab
text:
Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells. It was developed by Genentech. The most common adverse reactions (≥20%) include cytokine release syndrome, fatigue, rash, pyrexia, and headache. The most common grade 3 to 4 laboratory abnormalities (≥10%) include decreased lymphocyte count, decreased phosphate, increased glucose, decreased neutrophil count, increased u
brand slug:
wiki
category slug:
encyclopedia
description:
Monoclonal antibody
original url:
https://en.wikipedia.org/wiki/Mosunetuzumab
date created:
date modified:
2024-03-14T23:46:28Z
main entity:
{"identifier":"Q111697913","url":"https://www.wikidata.org/entity/Q111697913"}
image:
fields total:
13
integrity:
14